To characterize the BRD-binding activity of the small molecule BRD inhibitor PFI-3 to these SWI/SNF subunits, we developed a cellular thermal shift assay (CETSA) [22] with MT330 and LN229 GBM cells transduced with either an epitope-tagged BRG1 or BRM BRD. This evidence concerns the gene SMARCA2 and glioblastoma.